Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2280]

Geriatric oncology in resource-limited settings

Dr Enrique Soto Perez de Celis - National Institute of Medical Sciences, Mexico...

Geriatric oncology in resource-limited settings ( Dr Enrique Soto Perez de Celis - National Institute of Medical Sciences, Mexico City, Mexico )

Updates on HR-positive HER2-negative breast cancer

Dr Mariana Chavez - MD Anderson Cancer Center, Houston, USA

Updates on HR-positive HER2-negative breast cancer ( Dr Mariana Chavez - MD Anderson Cancer Center, Houston, USA )

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )

Immunotherapy developments and new agents for locally advanced NSCLC and SCLC

Dr Edgardo Santos - Florida Precision Oncology, Florida, USA

Immunotherapy developments and new agents for locally advanced NSCLC and SCLC ( Dr Edgardo Santos - Florida Precision Oncology, Florida, USA )

Updates on triple-negative breast cancer and immunotherapy

Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA

Updates on triple-negative breast cancer and immunotherapy ( Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA )

Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA

Dr Bruna Pellini - Moffitt Cancer Center, Tampa, USA

Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA ( Dr Bruna Pellini - Moffitt Cancer Center, Tampa, USA )

Predictive and prognostic biomarkers for immunotherapy in lung cancer

Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Predictive and prognostic biomarkers for immunotherapy in lung cancer ( Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain )

Gynaecological cancer: New targets and immunotherapy developments

Dr Mark Shahin - Jefferson Health, Philadelphia, USA

Gynaecological cancer: New targets and immunotherapy developments ( Dr Mark Shahin - Jefferson Health, Philadelphia, USA )

Potential benefit to response rates from trastuzumab added to perioperative...

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

Botensilimab plus balstilimab for metastatic heavily pretreated microsatellite...

Dr Andrea Bullock - Beth Israel Deaconess Medical Center, Boston, USA

Botensilimab plus balstilimab for metastatic heavily pretreated microsatellite stable colorectal cancer ( Dr Andrea Bullock - Beth Israel Deaconess Medical Center, Boston, USA )

Rationale for routine use of IORT for early breast cancer and data for specific...

Dr Hans-Christian Kolberg - Marienhospital Bottrop gGmbH, Bottrop, Germany

Rationale for routine use of IORT for early breast cancer and data for specific indications ( Dr Hans-Christian Kolberg - Marienhospital Bottrop gGmbH, Bottrop, Germany )

Lisocabtagene maraleucel is efficacious at treating R/R chronic lymphocytic...

Dr Tanya Siddiqi - City of Hope, Duarte, USA

Lisocabtagene maraleucel is efficacious at treating R/R chronic lymphocytic leukaemia/small lymphocytic lymphoma ( Dr Tanya Siddiqi - City of Hope, Duarte, USA )

More from ecancer